David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 293



161
TITLE: Stage IIIC1 versus IIIC2 endometrial adenocarcinoma of the uterus: Analysis of recurrence and patterns of toxicity  Full Text
AUTHORS: Bevan, C; Nagel, C; Boren, T; David Scott Miller ; Kehoe, S; Richardson, D; Albuquerque, K; Lea, J;
PUBLISHED: 2012, SOURCE: Gynecologic Oncology, VOLUME: 127, ISSUE: 1
INDEXED IN: CrossRef
IN MY: ORCID
162
TITLE: Survival outcomes after recurrence in endometrioid compared to papillary serous/clear cell carcinoma of the uterus  Full Text
AUTHORS: Nagel, C; Moron, A; Elwell, K; Kehoe, S; Lea, J; David Scott Miller ; Richardson, D;
PUBLISHED: 2012, SOURCE: Gynecologic Oncology, VOLUME: 127, ISSUE: 1
INDEXED IN: CrossRef: 2
IN MY: ORCID
163
TITLE: A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study.
AUTHORS: Moore, KN; Sill, M; David Scott Miller ; Disilvestro, P; De Geest, K; Rose, PG; Cardenes, HR; Mannel, RS; Farley, JH; Schilder, RJ; Fracasso, PM;
PUBLISHED: 2011, SOURCE: Journal of Clinical Oncology, VOLUME: 29, ISSUE: 15_suppl
INDEXED IN: CrossRef: 2
IN MY: ORCID
164
TITLE: A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study  Full Text
AUTHORS: David L Tait; John A Blessing; James S Hoffman; Kathleen N Moore; Nick M Spirtos; Jason A Lachance; Jacob Rotmensch; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 121, ISSUE: 1
INDEXED IN: Scopus CrossRef: 35
IN MY: ORCID
165
TITLE: Challenging prognostic factors for chemotherapy resistance in high-risk gestational trophoblastic neoplasia  Full Text
AUTHORS: Davidson, B; Nagel, C; King, M; Skorpinski, T; Kehoe, S; Richardson, D; David Scott Miller ; Lea, J;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID
166
TITLE: Does myometrial invasion confer a poorer prognosis in uterine adenosarcoma?  Full Text
AUTHORS: Nagel, C; Garcia-Soto, A; Richardson, D; Lea, J; David Scott Miller ; Kehoe, S;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID
167
TITLE: Outcomes of third line chemotherapy for recurrent and persistent cervical cancer  Full Text
AUTHORS: D.B Manders; S.C Purinton; J.S Lea; David Scott Miller ; S.M Kehoe; D.L Richardson;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef
IN MY: ORCID
168
TITLE: Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study
AUTHORS: Raymond J Osborne; Virginia Filiaci; Julian C Schink; Robert S Mannel; Angeles Alvarez Secord; Joseph L Kelley; Diane Provencher; David Scott Miller ; Allan L Covens; Janice M Lage;
PUBLISHED: 2011, SOURCE: Journal of Clinical Oncology, VOLUME: 29, ISSUE: 7
INDEXED IN: Scopus CrossRef: 122
IN MY: ORCID
169
TITLE: Predictive value of carcinoembryonic antigen and cancer antigen 125 in identifying mucinous ovarian tumors  Full Text
AUTHORS: D.B Manders; S.C Purinton; J.S Lea; D.L Richardson; David Scott Miller ; S.M Kehoe;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 123, ISSUE: 2
INDEXED IN: CrossRef: 1
IN MY: ORCID
170
TITLE: PRO: All patients with serous and clear cell carcinomas of the endometrium should receive chemotherapy as part of their treatment  Full Text
AUTHORS: Todd P Boren; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Clinical Ovarian Cancer, VOLUME: 4, ISSUE: 2
INDEXED IN: Scopus CrossRef
IN MY: ORCID
Page 17 of 30. Total results: 293.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service